Temsirolimus, an inhibitor of mammalian target of rapamycin

被引：140

作者：

Rini, Brian I. ^{[1
]}

机构：

[1] Cleveland Clin, Taussig Canc Ctr, Dept Solid Tumor Oncol & Urol, Cleveland, OH 44195 USA

来源：

CLINICAL CANCER RESEARCH | 2008年 / 14卷 / 05期

关键词：

D O I：

10.1158/1078-0432.CCR-07-4719

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：1286 / 1290

页数：5

共 31 条

[1] The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy [J].

Abraham, Robert T. ;

Gibbons, James J. .

CLINICAL CANCER RESEARCH, 2007, 13 (11) :3109-3114

[2]

AMATO RJ, 2006, P AN M AM SOC CLIN, V24, P4530

[3] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[4] TSC2 regulates VEGF through mTOR-dependent and -independent pathways [J].

Brugarolas, JB ;

Vazquez, F ;

Reddy, A ;

Sellers, WR ;

Kaelin, WG .

CANCER CELL, 2003, 4 (02) :147-158

[5] Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer [J].

Chan, S ;

Scheulen, ME ;

Johnston, S ;

Mross, K ;

Cardoso, F ;

Dittrich, C ;

Eiermann, W ;

Hess, D ;

Morant, R ;

Semiglazov, V ;

Borner, M ;

Salzberg, M ;

Ostapenko, V ;

Illiger, HJ ;

Behringer, D ;

Bardy-Bouxin, N ;

Boni, J ;

Kong, S ;

Cincotta, M ;

Moore, L .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5314-5322

[6] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme [J].

Chang, SM ;

Wen, P ;

Cloughesy, T ;

Greenberg, H ;

Schiff, D ;

Conrad, C ;

Fink, K ;

Robins, HI ;

De Angelis, L ;

Raizer, J ;

Hess, K ;

Aldape, K ;

Lamborn, KR ;

Kuhn, J ;

Dancey, J ;

Prados, MD .

INVESTIGATIONAL NEW DRUGS, 2005, 23 (04) :357-361

[7] Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma [J].

Cho, Daniel ;

Signoretti, Sabina ;

Dabora, Sandra ;

Regan, Meredith ;

Seeley, Apryle ;

Mariotti, Mauro ;

Youmans, Amanda ;

Polivy, Adam ;

Mandato, Lucy ;

McDermott, David ;

Stanbridge, Eric ;

Atkins, Michael .

CLINICAL GENITOURINARY CANCER, 2007, 5 (06) :379-385

[8] A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas [J].

Duran, I. ;

Kortmansky, J. ;

Singh, D. ;

Hirte, H. ;

Kocha, W. ;

Goss, G. ;

Le, L. ;

Oza, A. ;

Nicklee, T. ;

Ho, J. ;

Birle, D. ;

Pond, G. R. ;

Arboine, D. ;

Dancey, J. ;

Aviel-Ronen, S. ;

Tsao, M-S ;

Hedley, D. ;

Siu, L. L. .

BRITISH JOURNAL OF CANCER, 2006, 95 (09) :1148-1154

[9] Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus [J].

Duran, I. ;

Siu, L. L. ;

Oza, A. M. ;

Chung, T. -B. ;

Sturgeon, J. ;

Townsley, C. A. ;

Pond, G. R. ;

Seymour, L. ;

Niroumand, M. .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (12) :1875-1880

[10]

DUTCHER JP, 2007, P AN M AM SOC CLIN, V25, P5033

← 1 2 3 4 →